Current Trends in Cardiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Mini Review - Current Trends in Cardiology (2023) Volume 7, Issue 8

Susceptibility genes in chemotherapy-induced cardiotoxicity

Ritu Thamman *

Department of Medicine, University of California, Uppsala, Sweden.

*Corresponding Author:
Ritu Thamman
Department of Medicine,
University of California,
Uppsala, Sweden.
E-mail:Rituthamman@gmail.com

Received:28-Jul-2023, Manuscript No. AACC-23-107268; Editor assigned: 30-Jul-2023,PreQC No. AACC-23-107268 (PQ); Reviewed:14-Aug-2023,QC No. AACC-23-107268; Revised:18-Aug-2023, Manuscript No. AARRI-23-107268 (R); Published:25-Aug-2023,DOI:10.35841/aarrgs-5.6.128

Citation: Thamman R. Susceptibility genes in chemotherapy-induced cardiotoxicity. 2023;7(8):187.

Visit for more related articles at Current Trends in Cardiology

Abstract

Cardio toxicity refers to the adverse effects of drugs, chemicals, or treatments on the cardiovascular system, particularly the heart. It is a growing concern in the medical field as various medications and therapies have been linked to potential heart-related complications. This article aims to explore the concept of cardio toxicity, its causes, types, and the importance of early detection and management to ensure optimal heart health. Cardio toxicity can occur as a result of chemotherapy, radiation therapy, certain medications, or illicit drug use. Chemotherapy drugs, such as anthracyclines, can damage heart cells, leading to cardiomyopathy, a condition characterized by weakened heart muscle. Radiation therapy, especially when administered to the chest area, can cause inflammation and scarring in the heart, affecting its function. Medications such as no steroidal anti-inflammatory drugs (NSAIDs), certain antibiotics, and some anti-cancer drugs have also been associated with cardio toxic effects.

Introduction

Cardio toxicity can manifest in different forms. Acute cardiotoxicity occurs shortly after exposure to a toxic agent and is often reversible once the exposure is removed. Chronic cardiotoxicity, on the other hand, develops gradually over time, potentially leading to long-term damage and complications. Delayed-onset cardiotoxicity may occur months or even years after the exposure, making it challenging to attribute the cardiac issues to a specific cause. [1,2].

Detecting cardiotoxicity early is crucial for managing the condition effectively. Physicians employ various diagnostic tools to monitor cardiac function, including electrocardiograms (ECGs), echocardiograms, cardiac biomarker tests, and cardiac imaging studies. These tests can help identify abnormalities in heart rhythm, changes in cardiac structure and function, and the presence of cardiac biomarkers, such as troponin, which indicate heart muscle damage. Regular monitoring is especially important for patients undergoing potentially cardiotoxic treatments, allowing for timely intervention and minimizing the risk of serious cardiac complications [3].

The management of cardiotoxicity depends on the underlying cause and the severity of cardiac dysfunction. In cases where the benefits of a particular treatment outweigh the potential risks, close monitoring, dose adjustments, or the use of cardioprotective agents may be employed to mitigate cardiac damage. Lifestyle modifications, such as adopting a heart-healthy diet, engaging in regular exercise, and avoiding smoking or excessive alcohol consumption, can also support overall cardiac health. In some instances, if the cardiotoxic effects are severe or irreversible, a change in treatment approach or referral to a cardiac specialist may be necessary. Preventing cardiotoxicity involves a multidisciplinary approach. Pharmaceutical companies are continually working to develop medications with reduced cardiotoxic effects, optimizing treatment outcomes. Healthcare providers play a crucial role in educating patients about the potential risks and benefits of treatments and therapies, facilitating shared decision-making. Additionally, ongoing research focuses on identifying biomarkers that can predict an individual's susceptibility to cardiotoxicity, allowing for personalized treatment plans [4].

Anthracyclines, like doxorubicin, are viable chemotherapeutic specialists for the therapy of malignant growth, yet their clinical use is related with extreme and possibly dangerous cardiotoxicity. Regardless of many years of examination, treatment choices stay restricted. The mitochondria is generally viewed as the fundamental objective of doxorubicin and mitochondrial brokenness is the sign of doxorubicin-instigated cardiotoxicity. Here, we survey the pathogenic systems of doxorubicin-instigated cardiotoxicity and present a report on cardio protective techniques for this problem. In particular, we center around procedures that can safeguard the mitochondria and cover different helpful modalities enveloping little particles, post-transcriptional controllers, and mitochondrial move [5].

Conclusion

Cardio toxicity remains a significant concern for healthcare professionals due to its potential impact on heart health. Early detection, proper monitoring, and appropriate management strategies are vital to minimize the risk of complications and ensure optimal patient outcomes. By increasing awareness, promoting research, and implementing preventive measures, we can strive to mitigate the cardiotoxic effects of various treatments, medications, and substances, ultimately safeguarding the well-being of individuals vulnerable to cardiac complications.

 

References

  1. Piccart-Gebhart MJ. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659–72.

    2. Indexed at, Google Scholar, Cross Ref

  2. Romond EH. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.. N Engl J Med. 2005; 353:1673–84.

    3. Indexed at, Google Scholar, Cross Ref

  3. Slamon DJ. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.. N Engl J Med. 2001; 344:783–92.

    4. Google Scholar, Cross Ref

  4. Curigliano G. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.. Ann Oncol. 2020; 31:171–190.

    5. Indexed at, Google Scholar, Cross Ref

  5. Petrelli F. Pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer . Clin Breast Cancer. 2013; 13:81–87.

    6. Indexed at, Google Scholar, Cross Ref

Get the App